Last updated: February 24, 2026
What is the current status of Luveris in clinical development?
Luveris (lutropin alfa), a recombinant luteinizing hormone (LH), is approved for treatment of ovarian stimulation in women with severe LH deficiency. It is marketed by Ferring Pharmaceuticals but remains under ongoing clinical evaluation for expanded indications.
Clinical Trials Overview
As of December 2022, Ferring Pharmaceuticals has conducted multiple trials assessing Luveris:
- Ovarian stimulation in ART: Confirmed efficacy in combination with FSH for women with LH deficiency.
- Ovulation induction in women with hypogonadotropic hypogonadism: Approved indications are supported by Phase III data.
Ferring announced ongoing or planned trials focusing on:
- Use in younger women with ovarian insufficiency.
- Combination therapy with GnRH analogs.
No new pivotal trials listed on ClinicalTrials.gov since 2020, indicating treatment approval remains the primary indication focus.
Regulatory Updates
Luveris received FDA approval in 2000 and EMA approval in 2001. Since then, approval for expanded indications remains pending, with some regional approvals updating usage protocols—most notably, in Latin America and Asia.
How is the market for Luveris structured?
Market Size and Growth Drivers
The global ovarian stimulation market was valued at USD 1.43 billion in 2021. It is projected to grow at a CAGR of 8.2% from 2022 to 2029, primarily due to:
- Rising infertility rates globally.
- Increasing use of ART procedures.
- Advancements in controlled ovarian stimulation protocols.
Competitive Landscape
Luveris competes primarily with:
- Gonadotropins (urinary or recombinant FSH and LH products):
- Gonal-F (follitropin alfa).
- Menopur (Menotropins, a mix of FSH and LH).
- Other recombinant LH products:
- Lutropin alfa (specific to other indications).
Key market players include Merck (Merck Serono), Ferring Pharmaceuticals, and highly fragmented regional producers.
Regional Market Distribution
North America accounts for approximately 40% of the market; Europe 35%; Asia-Pacific 15%; Rest of the world 10%. Growth in Asia-Pacific is driven by:
- Increasing infertility treatments.
- Greater healthcare expenditure.
Pricing and Reimbursement
Pricing varies:
- In the US, a single Luveris injection costs approximately USD 300–500.
- Reimbursement depends on regional healthcare policies, with private insurers covering 60-80% in mature markets.
What are the forward projections for Luveris?
Revenue Projections
Limited direct revenue data exists for Luveris due to narrow indications and regional approvals. However:
- The ovarian stimulation market CAGR of 8.2% suggests increased revenues for all products in this class.
- If Luveris captures just 2% of this market by 2026, revenues could reach USD 30 million annually, considering the current market size.
Development and Commercialization Potential
Expanded indications, particularly for:
- Ovulation induction in women with hypogonadotropic hypogonadism.
- Use in younger populations.
Could expand the addressable patient population, potentially doubling or tripling revenue.
Strategic Factors Influencing Outlook
- Patent status: No recent patent filings for Luveris, raising potential generic entry risks.
- Regulatory pathways: Approval for new indications depends on clinical trial outcomes.
- Competitive pressure: Dominance of multi-recombinant gonadotropins, especially from Merck.
Key challenges and risks
- Limited current indications narrow revenue opportunities.
- Price competition from biosimilars and generics.
- Regional approval delays could restrain sales expansion.
Final considerations
Luveris remains a niche but stable product within infertility treatment. Its future growth hinges on securing new indications and expanding regional approvals. Market growth is tied to the broader ART industry expansion, with significant upside in emerging markets.
Key Takeaways
- Clinical activity for Luveris is limited to additional trials for existing indications; no major new approvals announced since 2020.
- The global ovarian stimulation market is expanding at approximately 8.2% CAGR, with Luveris positioned as a niche product.
- Revenue prospects depend on expanding indications, regional approvals, and competitive pricing.
- The product faces competition from other recombinant gonadotropins, with primary sales in North America and Europe.
- Market growth may benefit from increased infertility treatment adoption, especially in Asia-Pacific.
FAQs
Q1: Are there any ongoing clinical trials for Luveris besides current indications?
Current data shows no active trials focusing on new indications for Luveris as of late 2022, apart from ongoing assessments for existing uses.
Q2: What are the main regions where Luveris is approved?
Luveris is approved in North America, Europe, Latin America, and parts of Asia, with detailed regional variations in indications.
Q3: How does Luveris price compare with competing products?
In the US, a single dose costs USD 300–500. Competitors' prices vary based on region, with biosimilars potentially offering lower-price options.
Q4: What factors could limit Luveris’s market growth?
Limited indications, patent expiration risks, competitive pricing pressures, and regulatory delays could restrict growth.
Q5: Could Luveris benefit from combination therapies?
Potential exists but depends on clinical validation; currently, it is combined with FSH in specific ovarian stimulation protocols.
References
- Ferring Pharmaceuticals. (2022). Luveris (lutropin alfa) product information.
- MarketsandMarkets. (2022). Ovarian stimulation market size and forecast.
- ClinicalTrials.gov. (2022). Luveris clinical trial records.
- Statista. (2022). Infertility treatment market analysis.
- EMA. (2022). Drug approvals and indication updates.
